Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Farxiga and Trajenta in Healthy Volunteers
NCT04970940Phase 1Completed
- Sponsor
- AJU PHARM Co., Ltd.
- Start
- Jul 2020
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dapagliflozin and linagliptin in type 2 diabetes mellitus (T2DM), sponsored by AJU PHARM Co., Ltd. Primary endpoints: Area Under the Concentration-time Curve over the dosing interval at 24 hours and Maximum steady-state plasma concentration at 24 hours. Started Jul 2020; status: completed.
02
Drugs
dapagliflozinlinagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04970940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04970940.